BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (NASDAQ:CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.

Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612) in metastatic breast cancer and is not a commercially approved therapy. These engagements represent a prudent commercial-readiness step as BriaCell continues to evaluate BRIA-IMT and prepares for potential future commercialization planning and strategic discussions, subject to successful clinical development and applicable regulatory approvals.